Sihuan Pharmaceutical Holdings Group ( (HK:0460) ) has shared an update.
Sihuan Pharmaceutical Holdings Group Ltd. announced that its subsidiary, Meiyan Space Biological Technology, has received approval from China’s National Medical Products Administration for its Injectable Polycaprolactone Microsphere Facial Filler. This product, known as ‘PCL filler,’ marks a significant advancement in the medical aesthetics sector, offering long-lasting effects with a single treatment. The approval fills a gap in the company’s class III medical device offerings and aligns with its strategy to expand in the regenerative materials market. The market for such materials is rapidly growing, with the ‘PCL filler’ gaining popularity due to its effectiveness and consumer appeal, positioning Sihuan Pharmaceutical as a potential leader in this fast-growing sector.
More about Sihuan Pharmaceutical Holdings Group
Sihuan Pharmaceutical Holdings Group Ltd. is a company operating in the medical aesthetics industry, focusing on the development of regenerative materials and innovative pharmaceuticals. Its primary products include medical aesthetic injection materials, with a market focus on China.
YTD Price Performance: -2.00%
Technical Sentiment Signal: Strong Buy
Current Market Cap: $683.5M
For an in-depth examination of 0460 stock, go to TipRanks’ Stock Analysis page.